Patent expiration for one of the biggest branded products to lose exclusivity this year, Novartis AG’s Diovan (valsartan), came and went Sept. 21 without the launch of a competing generic for the single-ingredient antihypertensive agent.
The situation has raised questions about the ability of Ranbaxy Laboratories Ltd
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?